title: [Clinical factors associated with invasive pulmonary aspergillosis in patients with chronic pneumopathies and respiratory isolation of Aspergillus spp].
abstract: OBJECTIVE
  To determine clinical variables to distinguish invasive pulmonary aspergillosis (IPA) from colonization in patients with chronic pneumopathies with positive culture of Aspergillus spp. in respiratory samples.
  
  
  METHODS
  Retrospective cohort study including patients with respiratory isolations of Aspergillus spp. during a period of 10 years. IPA was evaluated according to the Bulpa criteria. Clinical variables were collected and a multiple logistic regression analysis was carried out.
  
  
  RESULTS
  Eighty-three patients with isolation of Aspergillus spp. from respiratory samples were included; 68.7% (n=57) of the patients had chronic obstructive pulmonary disease, 18% (n=15) pulmonary fibrosis and 13.3% (n=11) bronchial asthma. Twenty-two patients (26.6%) had IPA. The use of fluconazole (OR 4.49; CI 95% 1.5-13.4; P=.007), severe respiratory failure (OR 4.64; CI 95% 1.46-14.72; P=.009) and hospitalization time (OR 1.05; CI 95% 1.01-1.1; P=.006) were associated with IPA.
  
  
  CONCLUSIONS
  Prior use of fluconazole, severe respiratory failure and hospitalization time are associated with IPA in patients with chronic pneumopathies with respiratory isolation of Aspergillus spp.
authors.affiliation: Unidad de Enfermedades Infecciosas, Hospital General Universitario de Ciudad Real, Ciudad Real, España. juanjoco2005@yahoo.es
authors.forename: Juan José
authors.initials: JJ
authors.lastname: Castón
authors.forename: María José
authors.initials: MJ
authors.lastname: Linares
authors.forename: Antonio
authors.initials: A
authors.lastname: Rivero
authors.forename: Manuel
authors.initials: M
authors.lastname: Casal
authors.forename: Julián
authors.initials: J
authors.lastname: Torre-Cisneros
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000935:Antifungal Agents / Q000627:therapeutic use; D001230:Aspergillus / Q000302:isolation & purification*; D001249:Asthma / Q000150:complications; D001424:Bacterial Infections / Q000453:epidemiology; D002353:Carrier State / Q000175:diagnosis / Q000453:epidemiology / Q000382:microbiology; D002908:Chronic Disease; D015897:Comorbidity; D003428:Cross Infection / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology; D003937:Diagnosis, Differential; D004198:Disease Susceptibility; D005260:Female; D015725:Fluconazole / Q000627:therapeutic use; D006785:Hospitals, University / Q000706:statistics & numerical data; D006801:Humans; D015994:Incidence; D055744:Invasive Pulmonary Aspergillosis / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology* / Q000209:etiology / Q000382:microbiology; D007902:Length of Stay / Q000706:statistics & numerical data; D008168:Lung / Q000382:microbiology*; D008171:Lung Diseases / Q000150:complications*; D008297:Male; D008875:Middle Aged; D009761:Nystatin / Q000627:therapeutic use; D029424:Pulmonary Disease, Chronic Obstructive / Q000150:complications; D011658:Pulmonary Fibrosis / Q000150:complications; D012131:Respiratory Insufficiency / Q000209:etiology; D012189:Retrospective Studies; D012307:Risk Factors; D013030:Spain / Q000453:epidemiology
chemical_list: D000935:Antifungal Agents; D009761:Nystatin; D015725:Fluconazole